Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/01/2026 - J.P. Morgan Healthcare Conference

More about the company

Quotes

Date	Price	Change	Volume
13/01/26	30.62 $	-3.57%	3,717,360
12/01/26	31.76 $	-0.72%	2,867,877
09/01/26	31.99 $	+1.07%	2,876,223
08/01/26	31.65 $	-2.25%	3,037,526
07/01/26	32.38 $	+0.25%	3,880,157

Delayed Quote Nasdaq, January 13, 2026 at 07:47 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

31.76USD

Average target price

93.39USD

Spread / Average Target

+194.05%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 20:02:33 13/01/2026 GMT			5-day change	1st Jan Change
30.72 ^USD	-3.26%		-5.39%	-13.13%

12:16am	Appetite for weight-loss deals broader than visible, Viking CEO says	RE
01-12	Viking Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 02:15 PM

Capitalization	3.59B 3.08B 2.88B 2.67B 4.99B 324B 5.38B 33.07B 12.99B 155B 13.46B 13.19B 571B	P/E ratio 2025 *	-11.7x	P/E ratio 2026 *	-8.33x
Enterprise value	3B 2.58B 2.41B 2.24B 4.17B 271B 4.5B 27.67B 10.87B 130B 11.26B 11.03B 478B	EV / Sales 2025 *	-	EV / Sales 2026 *	-
Free-Float	92.4%	Yield 2025 *	-	Yield 2026 *	-

12:16am	Appetite for weight-loss deals broader than visible, Viking CEO says	RE
01-12	Viking Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 02:15 PM
01-12	Viking Therapeutics, Inc. Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity	CI
01-08	Viking Therapeutics Completes Enrollment in Phase 1 Trial of VK2735 Weight Loss Drug	MT
01-08	Viking Therapeutics, Inc. Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of Vv2735 in Obesity	CI
01-07	Viking Therapeutics, Inc. Announces Appointment of Neil Aubuchon as Chief Commercial Officer	CI
01-06	Viking Therapeutics Insider Sold Shares Worth $7,692,121, According to a Recent SEC Filing	MT
01-06	Viking Therapeutics Insider Sold Shares Worth $1,896,969, According to a Recent SEC Filing	MT
01-06	Viking Therapeutics Insider Sold Shares Worth $1,901,405, According to a Recent SEC Filing	MT
12-23	Health Care Up as Novo Nordisk Gains -- Health Care Roundup	DJ
12-23	Top pharma companies racing to launch first weight-loss pill	RE
12-23	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
12-12	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE

11-06	Viking Therapeutics highlights clinical data from VK2735 obesity program in presentation at ObesityWeek 2025	RE
29/10/25	Canaccord Genuity Initiates Viking Therapeutics at Buy With $106 Price Target	MT
23/10/25	Morgan Stanley Raises Price Target on Viking Therapeutics to $102 From $98, Keeps Overweight Rating	MT
22/10/25	Viking Therapeutics misses Q3 profit estimates	RE
19/08/25	Viking Therapeutics' Share Sell-Off After Obesity Drug Data 'Overreaction,' Truist Says	MT

Viking Therapeutics, Inc. Share Price

Equities

VKTX

US92686J1060

Biotechnology & Medical Research

Valuation: Viking Therapeutics, Inc.

Chart: Viking Therapeutics, Inc.

Latest news: Viking Therapeutics, Inc.

Last Transcript: Viking Therapeutics, Inc.

Analysts' recommendations: Viking Therapeutics, Inc.

Press Releases: Viking Therapeutics, Inc.

News in other languages: Viking Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Viking Therapeutics, Inc.

ETFs: Viking Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

01-12	Viking Therapeutics : Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity	PU
01-06	Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
11-26	Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference	AQ
11-20	Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735	AQ
11-19	Viking Therapeutics : November 2025 Corporate Presentation	PU

12-23	Kaum verändert - Novo Nordisk dick im Plus erwartet
19/08/25	MÄRKTE USA/Schwächer - Umschichtung aus Technologie- in defensive Aktien
19/08/25	MÄRKTE USA/Leichter - Rückzug aus Tech-Aktien
19/08/25	Wall Street ouvre en ordre dispersé, les détaillants au centre de l'attention en attendant Jackson Hole
19/08/25	USA-Les valeurs à suivre à Wall Street (actualisé)

1 day	-3.15%
1 week	-5.39%
Current month	-13.13%
1 month	-15.46%
3 months	-9.88%
6 months	-3.38%
Current year	-13.13%

1 week	29.54	33.35
1 month	29.54	37.83
Current year	29.54	36.17
1 year	18.92	43.15
3 years	8.25	99.41
5 years	2.02	99.41
10 years	0.88	99.41

Manager	Title	Age	Since
Brian Lian CEO	Chief Executive Officer	60	23/09/2012
Gregory Zante DFI	Director of Finance/CFO	55	03/01/2021
Marianne Mancini COO	Chief Operating Officer	61	03/01/2021

Director	Title	Age	Since
Lawson Macartney CHM	Chairman	68	30/04/2015
Brian Lian CHM	Chairman	60	23/09/2012
Matthew Foehr BRD	Director/Board Member	53	30/04/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
VIKING THERAPEUTICS, INC.	-3.26%	-5.39%	-21.40%	+241.45%	3.59B
ARGENX SE	+3.75%	+1.96%	+7.76%	+89.61%	48.01B
WUXI APPTEC CO., LTD.	+6.00%	+10.61%	+96.03%	+15.05%	41.97B
INSMED INCORPORATED	-1.67%	-6.09%	+138.50%	+745.24%	35.77B
BIONTECH SE	+4.47%	+8.76%	-6.20%	-26.45%	25.64B
GENMAB A/S	-0.74%	+6.77%	+37.30%	-21.62%	20.81B
WUXI BIOLOGICS (CAYMAN) INC.	+5.85%	+18.68%	+135.38%	-41.71%	19.92B
SUMMIT THERAPEUTICS INC.	-1.73%	-10.56%	-8.17%	+247.71%	13.14B
AKESO, INC.	-4.36%	+2.99%	+117.69%	+162.46%	14.9B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.68%	+11.30%	+185.68%	-	14.63B
Average	+0.69%	+4.33%	+68.26%	+156.86%	23.84B
Weighted average by Cap.	+1.96%	+3.60%	+71.13%	+161.66%

	2025 *	2026 *
Net sales	-	-
Net income	-306M -263M -245M -228M -425M -27.61B -458M -2.82B -1.11B -13.2B -1.15B -1.12B -48.67B	-439M -377M -352M -327M -610M -39.65B -658M -4.04B -1.59B -18.95B -1.65B -1.61B -69.88B
Net Debt	-587M -504M -470M -437M -815M -53B -879M -5.41B -2.12B -25.33B -2.2B -2.16B -93.42B	-450M -386M -360M -335M -625M -40.61B -674M -4.14B -1.63B -19.41B -1.69B -1.65B -71.57B